Skip to main navigation
Skip to main content
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Careers
  • Partnerships & Business Development
  • esperionscience.com
  • Contact Us
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources
  • Products
  • Science
    • Scientific Advisory Board
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants
  • Partnerships & Business Development
/investor-relations/newsroom

Newsroom

Esperion to Participate in January Investor Meetings
Dec 13, 2022
PDF Version
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
Dec 07, 2022
PDF Version
Esperion Appoints Ben Halladay Chief Financial Officer
Nov 16, 2022
PDF Version
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
Nov 09, 2022
PDF Version
Esperion to Participate in Jefferies London Healthcare Conference
Nov 02, 2022
PDF Version

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Current page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • Next page next ›
  • Last page last »

-

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-864-6774, or by email at corporateteam@esperion.com.

Leadership Information


Investors:
Alexis Callahan
investorrelations@esperion.com
(406) 539-1762

Corporate Inquiries & Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

Page Tools

Our Company

  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition

Patients

  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources

Products

  • Products

Science

  • Science
    • Scientific Advisory Board
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants

Careers

  • Careers

Partnerships & Business Development

  • Partnerships & Business Development

Investors & Media

  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

esperionscience footer

  • esperionscience.com

Contact Us

  • Contact Us

All trademarks and trade names are the property of their respective owners.

© 2023 Esperion Therapeutics, Inc. All rights reserved. 05/20 US-CRP-2000082

Utility

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines

Search

Share this page